The government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...

Union Minister Piyush Goyal said he held a meeting with Janet Truncale, Global Chair and CEO of EY, to discuss India's growing role in glob...

India faces a challenging global economic outlook for 2026-27. Geopolitical tensions and volatile oil prices are key concerns. However, Ind...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

The Union Budget is making a significant investment in India's health and innovation. Biopharma has been identified as a key strategic sect...

The Union Budget 2026-27 focuses on fortifying the Indian economy against global volatility through strategic investments in technology, he...

India's biopharmaceutical sector receives a significant boost with the Union Budget's ₹10,000 crore Biopharma SHAKTI programme. This initia...

Union Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceut...

Union Budget 2026: Finance Minister Nirmala Sitharaman has presented a six-point plan to boost India's economy. The strategy prioritizes ma...

The joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...

“A young scientist joining a company like Syngene can travel the world scientifically without ever having to leave Bengaluru. It provides o...

NITI Aayog CEO Amitabh Kant, Pfizer CEO Dr Alberta Bourla, National Institutes of Health (NIH) Director Dr Francis Collins and Food and Dru...

Ahead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...

India's intellectual property regulations and liabilities laws pose a major barrier to foreign companies, specially from the US, that preve...

India's health and innovative and biopharma sector deserves better attention from the government to help realise its full potential

The McKinsey report commissioned by the US-India Chamber of Commerce would be released at the US-India BioPharma and Healthcare Summit 2013...

Indian biotechnology sector is expected to become a five bn-dollar (around Rs 23,400 crore) industry by 2010, says a report.